Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
ALK tyrosine kinase inhibitor

Ensacove (ensartinib)

An approved treatment for ALK-Positive Lung Cancer.

FDA Approved (2024)by Xcovery Holdings, Inc. (developed with Betta Pharmaceuticals)
Preclinical
Phase 1
Phase 2
Phase 3
Approved
2024

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Ensartinib wherever you encounter it, plus the key facts at a glance.

Generic name
Ensartinib
Brand name
Ensacove
Development code
X-396
Drug class
ALK tyrosine kinase inhibitor
Manufacturer
Xcovery Holdings, Inc. (developed with Betta Pharmaceuticals)
How it's taken
Oral capsules, once a day

Ensacove (ensartinib) is a capsule taken once a day for adults with ALK-positive non-small cell lung cancer that is locally advanced or has spread.

  • It is for people whose cancer was found with an FDA-approved test and who have not taken an ALK inhibitor before[1].
  • The FDA approved it on December 18, 2024[2].
  • In the eXalt3 trial against crizotinib, the median time before the cancer grew or the person died was 25.8 months on Ensacove and 12.7 months on crizotinib[1].
  • Xcovery Holdings holds the US approval, and Xcovery says it developed ensartinib jointly with Betta Pharmaceuticals[2][1].
Follow Ensacove by email

We'll email you when Ensacove's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Ensartinib fits

Ensacove (ensartinib) is a once-daily ALK inhibitor capsule for adults with locally advanced or metastatic ALK-positive lung cancer who have not taken an ALK inhibitor before[1].

  • Crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa), brigatinib (Alunbrig) and lorlatinib (Lorbrena) are also FDA approved for ALK-positive lung cancer[10][11][8][7][9].
  • Neladalkib (Nelkarmi) received accelerated approval in November 2026 for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It is for people already treated for advanced or metastatic disease with either alectinib as their only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy[6].
  • Ensacove's eXalt3 trial compared it with crizotinib, and the ALTA-1L trial of brigatinib used crizotinib as its comparison too[1][7].
  • Trial Friend found no registered Phase 3 trial comparing Ensacove with alectinib, brigatinib, lorlatinib or neladalkib.
  • The Ensacove label does not cover people whose cancer has already been treated with another ALK inhibitor[1].
  • Anyone curious about ensartinib can ask their oncologist how its rash, liver and lab monitoring compares with the other first ALK inhibitor options.

How Ensartinib works

In ALK-positive lung cancer, a rearrangement in the ALK gene makes an abnormal, fused ALK protein that keeps sending growth signals to the cancer cells[1]. Ensartinib blocks ALK from switching on the proteins downstream of it, which stopped the growth of lab cell lines carrying ALK fusions and changes in ALK[1]. Ensartinib also blocks 2 related proteins, MET and ROS1, and it slowed ALK-driven human lung tumors grown in mice[1]. In eXalt3, brain tumors shrank in 59% of 17 people on Ensacove who had measurable brain metastases at the start[1].

Side effects and safety

What patients report

Ensacove has no boxed warning[1]. The label says it is not given to anyone who has had a severe allergic reaction to Ensacove or to FD&C Yellow No. 5 (tartrazine), a dye in the shell of the 100mg capsule[1]. The label's 10 warnings include lung inflammation, liver problems, skin reactions, slow heart rate and high blood sugar. The other warnings are vision problems, a rise in the muscle enzyme CPK, high uric acid, harm to an unborn baby and allergic-type reactions to tartrazine[1].

The figures below come from 458 people treated across 4 studies unless a trial is named[1].

Skin: Skin side effects occurred in 80% and were grade 3 in 14%[1]. Rash occurred in 72%, starting a median of 9 days after the first dose, and itching in 32%[1]. There was 1 case of DRESS, a severe drug reaction with rash, fever and organ involvement[1]. The label advises limiting direct sun during treatment and for at least 1 week after the last dose[1].

Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 5%, and was grade 3 in 1.3% and grade 4 in 0.4%[1]. The label says to watch for shortness of breath, cough and fever. The label also says to hold Ensacove right away if lung inflammation is suspected and to stop it for good if it is confirmed[1].

Liver: ALT rose in 59% and AST in 58%, with grade 3 ALT rises in 5%, and there was 1 case of drug-induced liver injury[1]. The median time to a first rise was 5.3 weeks[1]. Liver tests are checked before starting, every 2 weeks during the first cycle of treatment, then monthly and as needed[1].

Heart rate: A heart rate below 60 beats a minute occurred in 6%, and all cases were grade 1 or 2[1]. Heart rate is checked regularly[1].

Blood sugar: Blood sugar rose in 44% and was grade 3 in 2.5%[1]. Fasting blood sugar is checked before starting and from time to time after[1].

Eyes: Vision problems such as blurred or double vision, flashes of light and floaters occurred in 8%[1]. The label calls for an eye exam for new or worse vision symptoms[1].

Muscle enzyme: CPK, a blood test that can signal muscle damage, rose in 43% of the 203 people with results. The label says to report unexplained muscle pain, tenderness or weakness[1].

Uric acid: High uric acid was reported as a side effect in 6%, and uric acid is checked before starting and from time to time after[1].

Pregnancy: Ensacove can harm an unborn baby, and a pregnancy test is done before starting for anyone who could become pregnant[1]. The label calls for effective birth control during treatment and for 1 week after the last dose, for female patients and for male patients with partners who could become pregnant[1]. Breastfeeding is not advised during treatment and for 1 week after[1].

Most common: In eXalt3 the most common side effects on Ensacove were rash (66%), muscle and joint pain (36%), cough (31%) and constipation (31%). Other common ones were itching (30%), nausea (28%), swelling (27%), fever (22%) and tiredness (21%)[1]. Serious side effects occurred in 23%, most often pneumonia, and 1 person (0.7%) died of bronchopneumonia[1]. Of the 143 people treated in eXalt3, 12% stopped Ensacove for good because of side effects and 24% needed a lower dose, most often for rash[1].

Age 65 and older: In an exploratory look across the studies, serious side effects were more common in people 65 and older than in younger people (43% against 27%)[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Ensartinib

The label dose is 225mg by mouth once a day, at the same time each day, with or without food[1]. Capsules come in 25mg and 100mg strengths and are swallowed whole. They must not be crushed, chewed, opened or dissolved[1]. A missed dose is taken as soon as possible unless the next dose is due within 12 hours, and 2 doses are never taken on the same day[1]. After vomiting, no extra dose is taken[1]. Capsules are kept in the original bottle with its moisture-absorbing packet[1].

For side effects, the doctor may pause Ensacove or lower the dose to 200mg and then 150mg once a day[1]. A lowered dose is not raised again, and Ensacove is stopped for good in people who cannot tolerate 150mg[1].

Before starting: Liver tests, fasting blood sugar and uric acid are checked, and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong and moderate CYP3A inhibitors and inducers and P-gp inhibitors. These medicines may raise or lower ensartinib levels, though these effects have not been studied in people[1].

Liver: Ensacove is not used in people with severe liver impairment, which has not been studied, and people with moderate liver impairment are watched for more side effects[1].

Availability and cost

No generic available

Only available as the brand-name product.

Help paying for Ensacove

With private insurance, the drugmaker's copay card can lower what you pay for Ensacove. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for ALK-Positive Lung Cancer were open on November 18, 2026. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
Ensacove (Ensartinib)
Some details not published
  • Copay help

    XcoveryCares Co-Pay Assistance Program for commercially insured patients 18 or older in the US or a US territory whose private insurance does not cover the full cost. Not valid when any part of the prescription can be paid by Medicare, Medicare Advantage, Medigap, Medicaid, DoD, VA, TRICARE or another government program. Covers 1 calendar year and may be renewed. No income requirement. The page states no dollar amount or annual maximum. For questions, call 1-888-215-8384, Monday to Friday, 8 AM to 8 PM ET.

    For: private insurance · source

Good to know: Read on ensacove.com/financial-support on November 18, 2026; the page blocks plain downloads and was read through a page fetch. The page names only the co-pay program and an XcoveryCares patient enrollment form (PDF, could not be read as text) and offers sample appeal and medical necessity letters. No free-drug program, bridge supply or named specialty pharmacy appears on the page. A third-party drug price site lists 866-367-2260 for XcoveryCares, which does not appear on ensacove.com and was not used.

Checked on the drugmaker's official pages on November 18, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for ALK-Positive Lung Cancer

No charity fund for this condition is open right now. Funds reopen when they receive new donations; the foundations let you sign up to be told when one opens.

Status as each foundation showed it on November 18, 2026.

Every program and charity fund for ALK-Positive Lung Cancer →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

eXalt3 (NCT02767804) was a randomized, open-label Phase 3 trial of 290 adults with locally advanced or metastatic ALK-positive lung cancer who had not taken an ALK-targeted drug[1][3]. The trial compared Ensacove 225mg once a day (143 people) with crizotinib 250mg twice a day (147 people)[1][3]. People could have had 1 earlier chemotherapy, people with brain metastases that caused no symptoms could join, and people with cancer in the lining of the brain could not[1]. Results judged by reviewers who did not know the treatment, from the label[1]:

  • Time before the cancer grew or the person died: median 25.8 months on Ensacove and 12.7 months on crizotinib (hazard ratio 0.56)
  • Tumors shrank in 74% on Ensacove and 67% on crizotinib
  • In people with measurable brain metastases, brain tumors shrank in 59% of 17 on Ensacove and 21% of 24 on crizotinib
  • At the final overall survival analysis there was no statistically significant difference, with median survival of 63.2 months on Ensacove and 55.7 months on crizotinib (hazard ratio 0.88)

The trial's results were published in JAMA Oncology in 2021[4]. ClinicalTrials.gov lists eXalt3 as active and no longer recruiting[3].

Development history

Ensartinib was tested under the code X-396, and Xcovery says it was developed jointly with Betta Pharmaceuticals[3][2]. eXalt3 began in June 2016, with Xcovery Holdings as its lead sponsor[3]. The FDA approved Ensacove on December 18, 2024 for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer who have not taken an ALK inhibitor, based on eXalt3[2].

The current label is dated February 2026 and reports the final eXalt3 overall survival analysis. That analysis found no statistically significant difference from crizotinib[1].

Ask anything about Ensartinib
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore ALK-Positive Lung Cancer trials

Other ALK-Positive Lung Cancer treatments

Common questions about Ensartinib

▸What is Ensartinib (Ensacove)?

Ensacove (ensartinib) is a capsule taken once a day for adults with ALK-positive non-small cell lung cancer that is locally advanced or has spread. It is for people whose cancer was found with an FDA-approved test and who have not taken an ALK inhibitor before[1]. The FDA approved it on December 18, 2024[2]. In the eXalt3 trial against crizotinib, the median time before the cancer grew or the person died was 25.8 months on Ensacove and 12.7 months on crizotinib[1]. Xcovery Holdings holds the US approval, and Xcovery says it developed ensartinib jointly with Betta Pharmaceuticals[2][1].

▸How does Ensartinib work?

In ALK-positive lung cancer, a rearrangement in the ALK gene makes an abnormal, fused ALK protein that keeps sending growth signals to the cancer cells[1]. Ensartinib blocks ALK from switching on the proteins downstream of it, which stopped the growth of lab cell lines carrying ALK fusions and changes in ALK[1]. Ensartinib also blocks 2 related proteins, MET and ROS1, and it slowed ALK-driven human lung tumors grown in mice[1]. In eXalt3, brain tumors shrank in 59% of 17 people on Ensacove who had measurable brain metastases at the start[1].

▸What are the side effects of Ensartinib?

Ensacove has no boxed warning[1]. The label says it is not given to anyone who has had a severe allergic reaction to Ensacove or to FD&C Yellow No. 5 (tartrazine), a dye in the shell of the 100mg capsule[1]. The label's 10 warnings include lung inflammation, liver problems, skin reactions, slow heart rate and high blood sugar. The other warnings are vision problems, a rise in the muscle enzyme CPK, high uric acid, harm to an unborn baby and allergic-type reactions to tartrazine[1]. The figures below come from 458 people treated across 4 studies unless a trial is named[1].

Skin: Skin side effects occurred in 80% and were grade 3 in 14%[1]. Rash occurred in 72%, starting a median of 9 days after the first dose, and itching in 32%[1]. There was 1 case of DRESS, a severe drug reaction with rash, fever and organ involvement[1]. The label advises limiting direct sun during treatment and for at least 1 week after the last dose[1].

Lungs: Lung inflammation (interstitial lung disease or pneumonitis) occurred in 5%, and was grade 3 in 1.3% and grade 4 in 0.4%[1]. The label says to watch for shortness of breath, cough and fever. The label also says to hold Ensacove right away if lung inflammation is suspected and to stop it for good if it is confirmed[1].

Liver: ALT rose in 59% and AST in 58%, with grade 3 ALT rises in 5%, and there was 1 case of drug-induced liver injury[1]. The median time to a first rise was 5.3 weeks[1]. Liver tests are checked before starting, every 2 weeks during the first cycle of treatment, then monthly and as needed[1].

Heart rate: A heart rate below 60 beats a minute occurred in 6%, and all cases were grade 1 or 2[1]. Heart rate is checked regularly[1].

Blood sugar: Blood sugar rose in 44% and was grade 3 in 2.5%[1]. Fasting blood sugar is checked before starting and from time to time after[1].

Eyes: Vision problems such as blurred or double vision, flashes of light and floaters occurred in 8%[1]. The label calls for an eye exam for new or worse vision symptoms[1].

Muscle enzyme: CPK, a blood test that can signal muscle damage, rose in 43% of the 203 people with results. The label says to report unexplained muscle pain, tenderness or weakness[1].

Uric acid: High uric acid was reported as a side effect in 6%, and uric acid is checked before starting and from time to time after[1].

Pregnancy: Ensacove can harm an unborn baby, and a pregnancy test is done before starting for anyone who could become pregnant[1]. The label calls for effective birth control during treatment and for 1 week after the last dose, for female patients and for male patients with partners who could become pregnant[1]. Breastfeeding is not advised during treatment and for 1 week after[1].

Most common: In eXalt3 the most common side effects on Ensacove were rash (66%), muscle and joint pain (36%), cough (31%) and constipation (31%). Other common ones were itching (30%), nausea (28%), swelling (27%), fever (22%) and tiredness (21%)[1]. Serious side effects occurred in 23%, most often pneumonia, and 1 person (0.7%) died of bronchopneumonia[1]. Of the 143 people treated in eXalt3, 12% stopped Ensacove for good because of side effects and 24% needed a lower dose, most often for rash[1].

Age 65 and older: In an exploratory look across the studies, serious side effects were more common in people 65 and older than in younger people (43% against 27%)[1].

▸How is Ensartinib taken?

The label dose is 225mg by mouth once a day, at the same time each day, with or without food[1]. Capsules come in 25mg and 100mg strengths and are swallowed whole. They must not be crushed, chewed, opened or dissolved[1]. A missed dose is taken as soon as possible unless the next dose is due within 12 hours, and 2 doses are never taken on the same day[1]. After vomiting, no extra dose is taken[1]. Capsules are kept in the original bottle with its moisture-absorbing packet[1].

For side effects, the doctor may pause Ensacove or lower the dose to 200mg and then 150mg once a day[1]. A lowered dose is not raised again, and Ensacove is stopped for good in people who cannot tolerate 150mg[1].

Before starting: Liver tests, fasting blood sugar and uric acid are checked, and a pregnancy test is done for anyone who could become pregnant[1].

Other medicines: The label says to avoid strong and moderate CYP3A inhibitors and inducers and P-gp inhibitors. These medicines may raise or lower ensartinib levels, though these effects have not been studied in people[1].

Liver: Ensacove is not used in people with severe liver impairment, which has not been studied, and people with moderate liver impairment are watched for more side effects[1].

▸Is Ensartinib FDA approved?

Yes, Ensartinib (Ensacove) is FDA approved (2024) for the treatment of ALK-Positive Lung Cancer.

▸Is ensartinib FDA approved?

Yes. The FDA approved ensartinib as Ensacove on December 18, 2024.

Who it is for: Adults with locally advanced or metastatic ALK-positive non-small cell lung cancer, found with an FDA-approved test, who have not taken an ALK inhibitor.

Dose: The dose is 225mg by mouth once a day, with or without food.

Safety: The label has no boxed warning.

Company: Xcovery Holdings holds the approval.

More: ALK-positive lung cancer treatments compared

Source: FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC); [ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e)

▸What did the eXalt3 trial of ensartinib vs crizotinib show?

The median time before the cancer grew or the person died was 25.8 months on ensartinib and 12.7 months on crizotinib.

Tumor shrinkage: Tumors shrank in 74% on ensartinib and 67% on crizotinib.

Brain: Brain tumors shrank in 59% of 17 people on ensartinib and 21% of 24 on crizotinib.

Survival: The final analysis found no statistically significant difference in overall survival, with medians of 63.2 and 55.7 months.

Size: The trial enrolled 290 adults who had not taken an ALK inhibitor.

Source: [ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e)

▸What are the side effects of Ensacove?

Rash is the most common side effect of Ensacove, in 66% of people in eXalt3. Across 458 treated people, rash started a median of 9 days after the first dose.

Other common ones: Muscle and joint pain (36%), cough (31%), constipation (31%), itching (30%), nausea (28%) and swelling (27%).

Warnings: Lung inflammation, liver problems, skin reactions, slow heart rate, high blood sugar, vision problems, a rise in CPK, high uric acid and harm to an unborn baby.

Allergy: Ensacove is not used in people with a severe allergy to tartrazine, a yellow dye in the 100mg capsule.

Stopping: In eXalt3, 12% stopped for good because of side effects, and 24% needed a lower dose.

Source: [ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e)

▸Can ensartinib be used after another ALK inhibitor?

The Ensacove label covers only people who have not taken an ALK inhibitor before.

In the trial: eXalt3 excluded people who had taken an ALK-targeted drug, and allowed 1 earlier chemotherapy.

After other ALK inhibitors: The crizotinib (Xalkori), ceritinib (Zykadia), alectinib (Alecensa), brigatinib (Alunbrig) and lorlatinib (Lorbrena) labels each include a use in metastatic lung cancer. That use is not limited to a first ALK treatment.

Neladalkib: Nelkarmi has accelerated approval for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer. It is for people already treated for advanced or metastatic disease with either alectinib as their only ALK inhibitor, or 2 or more ALK inhibitors plus platinum chemotherapy.

Source: [ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e); [XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7); [ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e); [ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb); [ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db); [LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d); NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. U.S. National Library of Medicine, DailyMed · 2026-02. ENSACOVE (ENSARTINIB) CAPSULE [XCOVERY HOLDINGS, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1e1b2f79-678a-472a-b924-66909c8a4b2e
  2. Xcovery Holdings, Inc. via Business Wire (BioSpace copy) · 2024-12-18. FDA Approval of Ensartinib for ALK-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). https://www.biospace.com/press-releases/fda-approval-of-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer-nsclc
  3. ClinicalTrials.gov · 2026-11-18. eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients. https://clinicaltrials.gov/study/NCT02767804
  4. JAMA Oncology · 2021-11-01. Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial.. https://pubmed.ncbi.nlm.nih.gov/34473194/
  5. Xcovery Holdings, Inc. · 2026-11-18. Access & Financial Support - Ensacove. https://ensacove.com/financial-support/
  6. Nuvalent, Inc. · 2026-11. NELKARMI (neladalkib) tablets, for oral use: Full Prescribing Information. https://nuvalent.com/pdfs/nelkarmi-full-prescribing-information.pdf
  7. U.S. National Library of Medicine, DailyMed · 2026-01. ALUNBRIG (BRIGATINIB) TABLET, FILM COATED ALUNBRIG (BRIGATINIB) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db
  8. U.S. National Library of Medicine, DailyMed · 2026-08. ALECENSA (ALECTINIB HYDROCHLORIDE) CAPSULE [GENENTECH, INC.]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42c49deb-713b-427a-9670-08af08adcffb
  9. U.S. National Library of Medicine, DailyMed · 2026-06. LORBRENA (LORLATINIB) TABLET, FILM COATED [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b34d62d-e02a-4af3-bc0d-1571dd4ee76d
  10. U.S. National Library of Medicine, DailyMed · 2026-11. XALKORI (CRIZOTINIB) CAPSULE XALKORI (CRIZOTINIB) CAPSULE, COATED PELLETS [PFIZER LABORATORIES DIV PFIZER INC]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7
  11. U.S. National Library of Medicine, DailyMed · 2026-10. ZYKADIA (CERITINIB) TABLET, FILM COATED [NOVARTIS PHARMACEUTICALS CORPORATION]. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fff5d805-4ffd-4e8e-8e63-6f129697563e

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow Ensacove by email

We'll email you when Ensacove's FDA label changes, when the FDA acts on it, and when new trials for ALK-Positive Lung Cancer open. Unsubscribe anytime.

You'll get, for ALK-Positive Lung Cancer:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site